论文部分内容阅读
目的 为临床应用混合抗体进行瘤内注射放射免疫治疗提供实验依据。方法 在裸鼠荷人肝癌2.2.15移植瘤生长至1 cm时，瘤内分别或同时注射131I标记的抗癌胚蛋白（AFP）单克隆抗体（131I -AFP-IT）和131I标记抗乙型肝炎表面抗原单克隆抗体S102（131I- S102-IT），治疗后行SPECT显像观察标记抗体在肿瘤内的浓聚，并进行疗效观察。 结果 发现两种标记抗体联合治疗组肿瘤抑制率为76.5%，明显高于131I -AFP-IT组的53.1%及131I- S102-IT组的47.3%，抗体在肿瘤内的浓聚也明显高于单独应用组。结论 多种抗体混合应用瘤内注射放射免疫治疗可增加标记抗体在肿瘤内的浓聚，并能提高放射免疫治疗的疗效。
Objective To provide experimental basis for clinical application of mixed antibodies for intratumoral radioimmunotherapy. Methods When tumor xenograft 2.2.15 in nude mice grew to 1 cm, 131I-labeled anti-cancer protein (AFP) monoclonal antibody (131I-AFP-IT) and 131I-labeled anti-beta were injected intratumorly or simultaneously. Hepatitis surface antigen monoclonal antibody S102 (131I-S102-IT). After treatment, SPECT imaging was used to observe the concentration of labeled antibody in the tumor, and the efficacy was observed. The results showed that the tumor inhibitory rate was 76.5% in the combination of the two labeled antibodies, which was significantly higher than the 53.1% in the 131I-AFP-IT group and 47.3% in the 131I-S102-IT group. The concentration of the antibody in the tumor was also significantly higher than in the tumor. Apply groups individually. Conclusion Intratumoral injection of radioimmunotherapy with multiple antibody combinations can increase the concentration of labeled antibodies in tumors and improve the efficacy of radioimmunotherapy.